Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD

Wang, Jing; Lv, Huajie; Luo, Zhuojing; Mou, Shan; Liu, Jing; Liu, Chang; Deng, Shiying; Jiang, Youfan; Lin, Jiachen; Wu, Congcong; Liu, Xianhong; He, Jinzhi; Jiang, Depeng

doi:10.1186/s12931-018-0755-6

Cited by 34 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NGAL is attributed to activated neutrophils in response to smoke related airway inflammation as well as reactive oxygen species. It is one of the most extensively explored markers of ACO [13,77,78]. We found the level to be highest in ACO as compared to asthma, COPD and controls.…”

Section: Discussionmentioning

confidence: 58%

“…GM-CSF is another pleiotrophic and pro-inflammatory cytokine that promotes leucocyte survival and activation, and regulates mucosal immunity and inflammation. YKL-40 a secreted glycoprotein, produced by various cell types, including macrophages, neutrophils, and airway epithelium is reported to be involved in the pathogenesis of COPD, including bronchial neutrophilic airway inflammation and remodelling [77]. It has also been studied in ACO with a few conflicting reports.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO)

et al. 2020

View full text Add to dashboard Cite

Background: Asthma-COPD overlap (ACO) refers to a group of poorly studied and characterised patients reporting with disease presentations of both asthma and COPD, thereby making both diagnosis and treatment challenging for the clinicians. They exhibit a higher burden in terms of both mortality and morbidity in comparison to patients with only asthma or COPD. The pathophysiology of the disease and its existence as a unique disease entity remains unclear. The present study aims to determine whether ACO has a distinct metabolic and immunological mediator profile in comparison to asthma and COPD. Methods: Global metabolomic profiling using two different groups of patients [discovery (D) and validation (V)] were conducted. Serum samples obtained from moderate and severe asthma [n = 34(D); n = 32(V)], moderate and severe COPD [n = 30(D); 32(V)], ACO patients [n = 35(D); 40(V)] and healthy controls [n = 33(D)] were characterized using gas chromatography mass spectrometry (GC-MS). Multiplexed analysis of 25 immunological markers (IFN-γ (interferon gamma), TNF-α (tumor necrosis factor alpha), IL-12p70 (interleukin 12p70), IL-2, IL-4, IL-5, IL-13, IL-10, IL-1α, IL-1β, TGF-β (transforming growth factor), IL-6, IL-17E, IL-21, IL-23, eotaxin, GM-CSF (granulocyte macrophagecolony stimulating factor), IFN-α (interferon alpha), IL-18, NGAL (neutrophil gelatinase-associated lipocalin), periostin, TSLP (thymic stromal lymphopoietin), MCP-1 (monocyte chemoattractant protein-1), YKL-40 (chitinase 3 like 1) and IL-8) was also performed in the discovery cohort. Results: Eleven metabolites [serine, threonine, ethanolamine, glucose, cholesterol, 2-palmitoylglycerol, stearic acid, lactic acid, linoleic acid, D-mannose and succinic acid] were found to be significantly altered in ACO as compared with asthma and COPD. The levels and expression trends were successfully validated in a fresh cohort of subjects. Thirteen immunological mediators including TNFα, IL-1β, IL-17E, GM-CSF, IL-18, NGAL, IL-5, IL-10, MCP-1, YKL-40, IFNγ, IL-6 and TGF-β showed distinct expression patterns in ACO. These markers and metabolites exhibited significant correlation with each other and also with lung function parameters.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Wang et al (42) recently reported that plasma levels of NGAL was higher in patients with ACO than in asthma patients, and lower in ACO patients than in patients with COPD. The definition of asthmatic components was similar to our study, but our study did not show difference in NGAL level between ACO and non-ACO COPD.…”

Section: Discussionmentioning

confidence: 98%

Neutrophil gelatinase-associated lipocalin as a complementary biomarker for the asthma-chronic obstructive pulmonary disease overlap

Jo¹,

Kwon²,

Kim³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…People with asthma who have a long smoking history may develop ACO [20,21]. In such cases, plasma NGAL levels have been suggested to be useful for identifying patients in whom a change was observed from asthma alone to ACO [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Serum NGAL is elevated in patients with asthma and persistent airflow obstruction

Kawagoe

Kono

Togashi

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Neutrophilic airway inflammation is one of the features of severe asthma. Neutrophil gelatinase-associated lipocalin (NGAL), or lipocalin-2, is a glycoprotein associated with neutrophilic inflammation and can be detected in blood. Recently, blood NGAL levels have been reported to be elevated in chronic obstructive pulmonary disease. However, the clinical significance of serum NGAL levels in patients with asthma has not been elucidated. The aim of this study was to explore the association between serum NGAL level and clinical parameters in patients with asthma.Methods: Sixty-one non-smoking people with stable asthma were enrolled in this study. All patients underwent blood collection and pulmonary function tests. The associations between serum NGAL levels and clinical parameters were analyzed retrospectively. Results: Serum NGAL levels in patients with asthma and obstructive ventilatory disorder were higher than those in patients with asthma without obstructive ventilatory disorder (76.4 ± 51.4 ng/mL vs 39.3 ± 27.4 ng/mL, p=0.0019). Serum NGAL levels were correlated with forced expired flow at 50% of vital capacity %predicted and forced expired flow at 25% of vital capacity %predicted (r=-0.3373, p=0.0089 and r=-0.2900, p=0.0234, respectively). Results of a multiple regression analysis demonstrated that serum NGAL level was independently associated with obstructive ventilatory disorder.Conclusion: Serum NGAL levels were elevated in patients with asthma and obstructive ventilatory disorder. NGAL may be involved in airway remodeling possibly mediated by neutrophilic inflammation in asthma.

show abstract

Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD

Cited by 34 publications

References 40 publications

Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO)

Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO)

Neutrophil gelatinase-associated lipocalin as a complementary biomarker for the asthma-chronic obstructive pulmonary disease overlap

Serum NGAL is elevated in patients with asthma and persistent airflow obstruction

Contact Info

Product

Resources

About